Novo Nordisk A/S (NYSE:NVO) Receives Consensus Rating of “Hold” from Analysts

Shares of Novo Nordisk A/S (NYSE:NVO) have been assigned a consensus rating of “Hold” from the nineteen analysts that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, fourteen have issued a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $64.9375.

Several research analysts have commented on the company. BMO Capital Markets reissued a “market perform” rating and set a $47.00 target price on shares of Novo Nordisk A/S in a research note on Thursday, August 6th. Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Weiss Ratings raised shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. Nordea Equity Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Finally, Berenberg Bank set a $47.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, August 12th.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: China’s drug regulator accepted Novo Nordisk’s application for an oral version of Wegovy, an important regulatory milestone that could broaden access to its obesity treatment and support future growth in a major market. China drug regulator accepts Novo Nordisk’s application for oral Wegovy
• Positive Sentiment: Some investors view Novo Nordisk as potentially undervalued following its selloff. A report also suggests that shifting legal risks surrounding compounded or competing GLP-1 products could improve the outlook for branded treatments such as Ozempic and Wegovy. Novo Nordisk stock may be cheap as GLP-1 legal risks shift
• Neutral Sentiment: Novo Nordisk’s U.S. shares recently traded near $46, below the 50-day average but above the 200-day average. Its relatively low forward valuation may limit downside for value-oriented investors, but the stock’s price-to-earnings-growth ratio indicates that a recovery is not yet fully reflected in earnings expectations.
• Negative Sentiment: Deutsche Bank downgraded Novo Nordisk from Hold to Sell and cut its price target from 290 to 265 Danish kroner. The bank cited doubts about a return to growth, intensifying competition from Eli Lilly, a looming patent-related revenue cliff and weakness in the company’s development pipeline. Deutsche Bank cuts Novo Nordisk to Sell after earnings
• Negative Sentiment: Investor concerns were reinforced by mixed second-quarter results and the late-stage failure of cardiovascular drug candidate Ziltivekimab, which Deutsche Bank reportedly considers effectively removed from the company’s near-term growth prospects. Novo’s 2027 growth rebound faces fresh doubts

Institutional Investors Weigh In On Novo Nordisk A/S

Several hedge funds have recently modified their holdings of the company. Godfrey Financial Associates Inc. bought a new position in Novo Nordisk A/S in the fourth quarter valued at about $25,000. Transamerica Financial Advisors LLC boosted its stake in shares of Novo Nordisk A/S by 201.5% during the fourth quarter. Transamerica Financial Advisors LLC now owns 603 shares of the company’s stock valued at $31,000 after purchasing an additional 403 shares in the last quarter. Johnson Financial Group Inc. grew its holdings in shares of Novo Nordisk A/S by 128.0% during the third quarter. Johnson Financial Group Inc. now owns 684 shares of the company’s stock worth $38,000 after purchasing an additional 384 shares during the last quarter. Scarborough Advisors LLC bought a new stake in shares of Novo Nordisk A/S during the first quarter worth about $26,000. Finally, Continuum Advisory LLC acquired a new position in shares of Novo Nordisk A/S in the second quarter valued at approximately $38,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 0.0%

Shares of NVO opened at $45.59 on Monday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $64.16. The firm has a market cap of $203.56 billion, a price-to-earnings ratio of 11.15, a PEG ratio of 4.08 and a beta of 0.76. The business’s fifty day moving average is $48.03 and its 200-day moving average is $43.86.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. The business had revenue of $11.98 billion during the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%. Equities analysts anticipate that Novo Nordisk A/S will post 3.45 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a dividend, which was paid on Tuesday, August 25th. Stockholders of record on Monday, August 17th were issued a dividend of $0.5786 per share. The ex-dividend date was Monday, August 17th. This represents a dividend yield of 258.0%. Novo Nordisk A/S’s dividend payout ratio is 20.05%.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.